LCM
TPST icon

Laurion Capital Management’s Tempest Therapeutics TPST Stock Holding History

Laurion Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-113
Closed -$461K – 1697
2017
Q4 		$461K Buy
+113
New +$474K ﹤0.01% 1187

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Laurion Capital Management's TPST Position: Q1 2018 in Review

Laurion Capital Management sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 113 shares — an estimated $461K sold.

Laurion Capital Management first reported a position in TPST in Q4 2017 and held it in 1 quarter. The position peaked at $461K in Q4 2017. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

  • Laurion Capital Management reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Laurion Capital Management sold 113 Tempest Therapeutics shares in Q1 2018, an estimated $461K.
  • Laurion Capital Management first reported a position in Tempest Therapeutics in Q4 2017 and held it in 1 quarter.
  • Laurion Capital Management's Tempest Therapeutics position peaked at $461K in Q4 2017.
  • 41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on Laurion Capital Management's 13F filing for Q1 2018, filed 14 May 2018.